Search this blog

Loading...

Wednesday, 29 February 2012

Research: Grey matter lesions


Background: The endoplasmic reticulum (ER) stress pathway may play a role in the pathogenesis multiple sclerosis (MS), and while ER stress-associated molecules have been demonstrated in white matter (WM) lesions, these have not been analysed in grey matter (GM) demyelination.

Objective: The objective was to characterise the type and frequency of GM lesions and establish expression profiles of ER stress- and hypoxia (Lack of oxygen)-associated markers.

Methods: Sections from 16 MS cases and 12 non-MS controls were stained for ER stress molecules (BiP and CHOP) and hypoxia-associated D110 antigen.

Results: Of the GM lesions analysed, 24% were type 1 (continuous between GM and WM), 22% were type 2 (entirely within GM) and the majority (54%) were type 3 (extending from pia mater). Comparison of GM lesions, MS normal-appearing grey matter (NAGM) and non-MS control tissue showed that NAGM, type 1 and type 3 lesions all had significantly increased levels of CHOP compared to controls. According to morphological and dual-labelling criteria, the majority of CHOP-positive cells were microglia. Approximately 50% of GM lesions contained D110-positive cells.

Conclusion: These data suggest that ER stress plays an important role in GM lesion development and may be critical in activation of microglia in pre-lesional NAGM. The high number of lesions containing D110-positive cells suggests a role for hypoxic-like insult in GM lesion development.

Inside of a cell

There are markers associated with the misfolding of protein strucutures in the protein factories (endoplasmic reticulum) of the cells in grey matter lesions in MSers. The production of CHOP favours the production of cell death, because it causes down regulation of mitochondrial protein Bcl-2, that controls and protects cells from death. This therefore favouring a pro-cell death drive at the mitochondria (the energy powerhouse of the cell) by proteins that cause mitochondrial and cell damage. These authors suggest that there may be damage caused by hypoxia. This is lack of oxygen, which occurrs in stroke where it is associated with blocked vessels. However, these molecules are associated with patholgy. This study tells us that there are damaging processes occuring in MS lesions.


Research:Primary oligodendrocyte death does not elicit anti-CNS immunity

Locatelli et al. Primary oligodendrocyte death does not elicit anti-CNS immunity. Nature Neuroscience (2012) doi:10.1038/nn.3062 [Epub ahead of print]

Anti-myelin immunity is commonly thought to drive multiple sclerosis, yet the initial trigger of this autoreactivity remains elusive. One of the proposed factors for initiating this disease is the primary death of oligodendrocytes. To specifically test such oligodendrocyte death as a trigger for anti-CNS immunity, we inducibly killed oligodendrocytes in an in vivo mouse model. Strong microglia-macrophage activation followed oligodendrocyte death, and myelin components in draining lymph nodes made CNS antigens available to lymphocytes (white blood cells) . However, even conditions favoring autoimmunity—bystander activation, removal of regulatory T cells, presence of myelin-reactive T cells and application of demyelinating antibodies—did not result in the development of CNS inflammation after oligodendrocyte death. In addition, this lack of reactivity was not mediated by enhanced myelin-specific tolerance. Thus, in contrast with previously reported impairments of oligodendrocyte physiology, diffuse oligodendrocyte death alone or in conjunction with immune activation does not trigger anti-CNS immunity.
When I first read the comment in the blogger comments that the "Neurodegenerative hypothesis for the causes of MS is obsolete and researchers should be looking at the immune system and not the CNS" I thought that they were taking about the neurodegenerative hypothesis in progressive MS. To think that this is caused by influences outside the CNS and the immune system, is just pants, because I do not think the (lymphocyte) immune system is the problem there.

However
the neurodegenerative hypothesis is a hypothesis (idea) not about nerve damage (neurodegenerative) but an idea about oligodendrocyte damage, so gliadegenerative. This study is looking into the idea that oligodendrocyte damage is a trigger for immune attack in the first place.

As you know when you look at MS there is evidence of oligodendrocyte damage often in the absence of lymphocytes (a type of white blood cell), which some people think cause the problems with multiple sclerosis. This oligodendrocyte damage is thought by some, to trigger an immune attack of more oligodendrocytes. What causes the oligodendrocyte damage is unproven some may say viral attack others will say an inappropriate immune attack. So what did this study do?

They made a genetically-engineered mouse where the myelin-forming cells called oligodendrocytes make a target for the diptheria toxin which in normal mice would do nothing, but in these genetically engineered mice it causes the destruction of the oligodendrocytes so you have oligodendrocyte death so what happened next? Did the mice develop multiple sclerosis-like disease, even when in an inflammation-prone state? Well the answer is NO....so the conclusion that death of oligodendrocytes is not enough to cause immune attack of further oligodendrocytes. So we have to think about a different way that multiple sclerosis can be triggered. The solution is we should look outside the brain to work how MS starts. Hmmm not so sure.

Now the first thing that some of you will say is that, this is animal work and animals do not get MS and so blah, blah, blah.....so once you decide to read-on, you have moved away from this counter-productive response.

Then there are the others that will say that this study shows that MS is not an autoimmune disease caused by and causing oligodedendrocyte destruction. Indeed there are many like Prof G that think that this work will further support their view that the cause of MS is the work of some thing like a virus and this autoimmunity stuff is all guff. This is the message that this paper is attempting to get across........ they may be right, so bring on the Charcot Project. They killed oliogdendrocytes and caused demyelination but this did not lead to lymphocyte activation and did not cause an MS-like disease. They looked but could not find evidence that damage to oligodendrocytes can trigger MS attacks.

However, the problem of getting experiments that essentially do not work as planned could mean that rather than the idea being wrong, the wrong experimental design was used. So the autoimmuners still have a way to keep their beliefs and accomodate this new study.

So what did the study show? Well if you kill oligodendrocytes you get demyelination and animals (and presumably humans) develop neurological sysmptoms as a consequence of demyelination. Indeed in this study the mice actually died and this is perhaps a problem as this down-hill spiral (of about 2-3 weeks) may have been too quick for a proper destructive autoimmune response to develop. This takes time in animals and humans.
They did try and reduced the amount of toxin to limit the amount of nerve damage and did this over months and still no MS-like disease. The researchers were looking mainly in the brain for the autoimmune response, when the autoimmune response may accumulate first in the spinal cord of mice as we learned previously (can you remember the gate in the lumbar spinal cord?)

Now next point they show that if you loose myelination, nerves are vulnerable to nerve damage. Indeed in this study the pictures tended to suggest that nerve loss may be dominant effect, as they really did not present very good evidence of long-standing demyelinated nerves, which we think occurs in MS.

They showed that they could not find evidence that the damage created by loss of oligodendrocytes in the brain led to lymphocyte stimulation in the lymph glands. However, the white blood cells they used to try and cause the MS-like disease, do not do their supposed job in some peoples hands. There are a few more experiments that could have been done that would clarify this, but we can say that for any piece of work.

Is this result surprising? Well perhaps not because there have been studies, in other similar genetically-engineered mice that show dysmyelination and demyelination and the development of autoimmunity was not yet reported. The strain of mouse they used has low susceptibility to MS-like disease, so maybe they did not model the genetic predispositions well enough as we know that many different factors come into play when MS is triggered.

However maybe the autoimmune hypothesis of MS is wrong and this is further evidence to support that view. Alternatively it may be that the anti-myelin autoimmune response is wrong and that the target in oligodendrocytes is something else. Time will tell. However if autoimmunity is a problem in MS, it is more likely that it is first stimulated in the lymph glands and then the damaging cells enter the brain. This is because the lymph glands are structurally specialised for this operation, the brain is not.

If indeed you can induce robust demyelination, without losing too many nerves, and killing the mice,
These animals could be of real use in working how to promote remyelination. In this paper they report some evidence for remyelination so maybe just maybe.

Tuesday, 28 February 2012

Team G News: Auf wiedersehen Pet

This week we say Auf Wiedersehen to our Prima German Student ...Caren, who is a regular blog reader.

Caren and Jo being wicked at Halloween selling cakes for a good cause

Congrats to Team G and the EyeDoctor for raising another wad of cash for MS charity at the Valentine's Day Bake a couple of Weeks Ago.

P.S. The MouseDoc's CarrotCake sold like hot cakes!

Education: Diagnosis of MS

Polman CH et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Anal Neurol 68:292-302

New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis. The use of imaging for demonstration of dissemination of central nervous system lesions in space and time has been simplified, and in some circumstances dissemination in space and time can be established by a single scan. These revisions simplify the Criteria, preserve their diagnostic sensitivity and specificity, address their applicability across populations, and may allow earlier diagnosis and more uniform and widespread use.
Diagnostic criteria for multiple sclerosis (MS) include clinical and paraclinical laboratory assessments emphasizing the need to demonstrate dissemination of lesions in space (DIS) and time (DIT) and to exclude alternative diagnoses. Although the diagnosis can be made on clinical grounds alone, magnetic resonance imaging (MRI) of the central nervous system (CNS) can support, supplement, or even replace some clinical criteria, as most recently emphasized by the so-called McDonald Criteria of the International Panel on Diagnosis of MS. The McDonald Criteria have resulted in earlier diagnosis of MS with a high degree of both specificity and sensitivity, allowing for better counseling of patients and earlier treatment.

Since the revision of the McDonald Criteria in 2005, new data and consensus have pointed to the need for their simplification to improve their comprehension and utility and for evaluating their appropriateness in populations that differ from the largely Western Caucasian adult populations from which the Criteria were derived. In May 2010 in Dublin, Ireland, the International Panel on Diagnosis of MS (the Panel) met for a third time to examine requirements for demonstrating DIS and DIT and to focus on application of the McDonald Criteria in pediatric, Asian, and Latin American populations.


This article can now be downloaded and viewed for free, to check out diagnosis of MS.

Research: A microscope reveals more than a magnifying glass. MRI imaging

Epub ahead of print: Sinnecker et al. Multiple Sclerosis Lesions and Irreversible Brain Tissue Damage: A Comparative Ultrahigh-Field Strength Magnetic Resonance Imaging Study. Arch Neurol. 2012 Feb 20.

BACKGROUND: In current clinical practice, T2-weighted magnetic resonance imaging (MRI) is commonly applied to quantify the accumulated multiple sclerosis (MS) lesion load, whereas T1-weighted sequences are used to differentiate oedema (swelling), blood-brain barrier breakdown by contrast enhancement, and irreversible brain tissue damage (commonly called "black holes" owing to the loss of signal intensity in T1-weighted sequences). Black holes are histopathologically associated with axonal loss and severe tissue destruction. In addition, double inversion recovery techniques were developed to improve the sensitivity to cortical (in the grey matter) lesions.


OBJECTIVE: To demonstrate the potential of ultrahigh-field 3-dimensional T1 weighted imaging using magnetization-prepared rapid acquisition and multiple gradient-echoes (MPRAGE) to detect and characterize white and gray matter pathology in MS.

METHODS: Twenty patients with relapsing-remitting MS and 14 healthy controls underwent 7-Telsa brain MRI, using a 24-channel receive head coil, and a subgroup of 18 patients with relapsing-remitting MS also underwent 1.5-T brain MRI. The imaging protocol included 2-dimensional T2-weighted fast low-angle shot (FLASH) and turbo inversion recovery magnitude (TIRM) sequences. For 3-dimensional T1-weighted imaging, the MPRAGE sequence was used. Each sequence was initially examined independently in separate analyses by an investigator blinded to all other data. In a second study, all detected lesions were retrospectively analyzed in a side-by-side comparison of all sequences.

RESULTS: By use of 7-Telsa, T2-weighted FLASH imaging, 604 cerebral (brain) lesions were detected in the patients with relapsing-remitting MS (mean, 30.2 lesions per patient [range, 2-107 lesions per patient]), but none were detected in healthy controls.
Cortical (grey matter) pathology was visible in 10 patients (6 cortical lesions and 37 leucocortical lesions). Within the 7-T acquisitions, each lesion detected at T2-weighted sequences and/or double inversion recovery sequences was also clearly delineated on corresponding MPRAGE sequences in side-by-side analysis. However, at 1.5 T, the MPRAGE images depicted only 452 of 561 lesions visualized in T2-weighted sequences and/or double inversion recovery sequences. In contrast, when analyzing each sequence separately, we found that the 7-T MPRAGE depicted more lesions than the 7-T FLASH (728 lesions vs 584 lesions), and almost twice as many as the 1.5-T MPRAGE (399 lesions). The 7-T MPRAGE also improved the detection of cortical and leukocortical lesions (15 lesions vs 58 lesions).


CONCLUSIONS: At ultrahigh-field strength, T1-weighted MPRAGE is highly sensitive in detecting MS plaques within the white and the gray brain parenchyma. Our results indicate structural damage beyond demyelination in every lesion depicted, which is in accordance with postmortem histopathological studies. The 7-T MPRAGE clearly delineated every cortical lesion that was visualized by any other MRI sequence at 1.5 or 7 T.

If you look through a microscope you will see more than using a magnifying glass and so it is not surprising that with a 7 tesla machine you see more than with the standard 1.5 telsa or the more high-powered 3 telsa machines. However if you look through a microscope you still often see more than can be see using MRI, the advantage of the latter is that is an imaging tool for the living. With this high powered imaaging it will show us that the disease is even more active than previously shown as it will detect more lesions comming and going

Cognitive rehabilitation in MS

Filippi et al. Multiple Sclerosis: Effects of Cognitive Rehabilitation on Structural and Functional MR Imaging Measures--An Explorative Study. Radiology. 2012 Mar;262(3):932-40. 

"This study shows that cognitive rehabilitation in MS'ers with cognitive dysfunction may work by recruiting new areas of the brain. This implies that you can train your brain to cope with damage and to compensate for the damage. In other words these results underpin the concept of brain training; we know this works for motor tasks (e.g. walking, skipping, skiing, etc.) why shouldn't it work for cognitive tasks? The problem is  that MS is a progressive disease so ongoing damage may undermine the adaptive responses  with time. More reason to do this in combination with a DMT that suppresses ongoing damage."

Purpose: To evaluate brain changes after cognitive rehabilitation in MS'ers with clinically stable relapsing-remitting MS (RRMS) by using neuropsychologic assessment and structural and functional MRI techniques. 

Structural MRI: delineates the anatomy of the brain, for example lesions and atrophy or shrinkage of the brain.

Functional MRI: delineates function of the brain; how much oxygen and blood a part of the brain requires when doing a particular task. 

Materials and Methods: 20 with RR MS and cognitive deficits at baseline were randomly assigned to undergo treatment (n = 10), which entailed computer-assisted cognitive rehabilitation of attention and information processing and executive functions, or to serve as a control subjects (n = 10) without cognitive rehabilitation. All patients underwent a standardized neuropsychologic assessment and MR imaging at baseline and after 12 weeks. Changes in gray matter (GM) volumes on 3D images and changes in normal-appearing white matter (NAWM) architecture on were assessed. Changes in functional activity at functional MR imaging during the Stroop task and at rest were also investigated. 

Stroop task: this is a cognitive test that require some thought

Results: As compared with their performance at baseline, the MS'ers in the treatment group improved at tests of attention and information processing and executive functions. Neither structural modifications to GM volume nor modifications to NAWM architecture were detected at follow-up in both groups. Functional MR imaging demonstrated modifications of the activity of several areas of the brain* at rest in the treatment group compared with the control group. In the treatment group, functional MR imaging changes were correlated with cognitive improvement (P < .0001 to .01). 

* For those of you who want to know these areas included the posterior cingulate cortex/precuneus and dorsolateral prefrontal cortex during the Stroop task, as well as modifications of the activity of the anterior cingulum,  posterior cingulate cortex  and/or precuneus, left dorsolateral   prefrontal cortex and right inferior parietal lobule. 


Conclusion: Rehabilitation of attention and information processing and executive functions in RR MS may be effected through enhanced recruitment of brain networks subserving the trained functions.

Monday, 27 February 2012

MS Research Day 2012: Grey matter talk

Next vid up is Dr Klaus Schmierer's talk on his latest research:

White matter? Grey matter? The whole brain matters!


Leave your comments and questions for Dr Klaus on the Shift.ms website.

Treatment switch for suboptimal response

Rio et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol. 2012 Jan 31

Background: Therapy for multiple sclerosis (MS) has a partial efficacy, and a significant proportion of treated patients will develop a suboptimal response with first line disease-modifying drugs (DMD). Therapy switch in patients with MS can be a strategy after a treatment failure. We studied the change in clinical activity after switching of first-line DMD because of a treatment failure.

Methods: Relapsing-remitting multiple sclerosis (RRMS) patients treated with interferon-beta (IFNB) or glatiramer acetate (GA) were divided into (i) patients without change in DMD, (ii) patients with a change in DMD because of a poor response, and (iii) those with a change in DMD without relation with response. Annualized relapse rate (ARR) and relapse-free proportions were analyzed.

Results: We identified 923 patients with RRMS. Of the 180 who experienced a change because of suboptimal response, 90 switched to another first-line DMT, 38 to mitoxantrone, and 52 to natalizumab. Median ARR in the pre-DMD period on first DMD and second DMD was the following: 1, 1, and 0 for switchers from IFNB to another IFNB (P = 0.0001); 0.67, 1, and 0 for switchers from GA to IFNB (P = 0.01); 1, 1, and 0 for switchers from an IFNB to GA (P = 0.02); 1.1, 1.5, 0.2 for switchers from IFNB or GA to mitoxantrone (P = 0.0001); 0.9, 1, 0 for switchers from IFNB or GA to natalizumab (P = 0.0001).

Conclusions: In patients with RRMS who have a poor response, switch to another DMD may reduce the clinical activity of the disease.


"This study shows that when first line DMDs (IFN-beta and GA) do not have optimal response it is worth switching to another treatment. As expected, a switch from first line DMD to natalizumab or mitoxantrone was beneficial. But it was interesting that even a switch from one IFN to another IFN, higher and even lower dose, can reduce the relapse rate. It is important to note what treatment failure/ disease breakthrough/ sub-optimal response is considered: a single mild relapse in the first months of treatment does not qualify."